Diabetes
Latest News
WHO plans to declare common sweetener as possible carcinogen
Aspartame would join the “possibly” carcinogenic group, which includes gasoline engine exhaust and working as a dry cleaner.
Commentary
Tirzepatide: Therapeutic titan or costly cure?
Positioning tirzepatide as the first injectable of choice after oral treatment escalation with metformin and an SGLT2 inhibitor may remain an...
Latest News
CGM alarm fatigue in youth?
Sometimes alarm thresholds generate too many alarms – which in turn might lead patients to ignore the devices.
Commentary
Beta cells from stem cells: Nearing a cure for type 1 diabetes?
The patients were producing insulin, they had positive C-peptide levels, and it showed that these beta cells work when given to human beings.
Latest News
FDA OKs pancreatic islet cell therapy for type 1 diabetes
“Today’s approval ... provides individuals living with type 1 diabetes and recurrent severe hypoglycemia an additional treatment option to help...
Conference Coverage
Once-weekly basal insulin nears market for type 2 diabetes
“I feel that weekly insulins have the potential to become transformational as preferred options for basal insulin replacement in people with type...
Conference Coverage
ADA: Screen all with type 2 diabetes for fatty liver disease
The ADA now advises screening all adults with type 2 diabetes or prediabetes, particularly those with obesity or cardiometabolic risk factors or...
Latest News
SAFE algorithm detects liver disease in general population
Scoring system was developed and validated to detect clinically significant (greater than stage 2) fibrosis in patients with NAFLD in primary care...
Conference Coverage
Children with type 2 diabetes face dire complications as young adults
Arterial stiffness and worsened cardiac function often appear in these children within 2-5 years of diagnosis and seem driven in part by the...
Conference Coverage
Cagrilintide with semaglutide: A way to prevent diabesity?
“These data support further investigation of CagriSema in people with type 2 diabetes in longer and larger phase 3 studies.”